Niagen Bioscience (NAGE) Gross Margin (2010 - 2026)

Niagen Bioscience (NAGE) has 17 years of Gross Margin data on file, last reported at 63.47% in Q1 2026.

• On a quarterly basis, Gross Margin rose 5.0% year-over-year to 63.47% in Q1 2026; TTM through Mar 2026 was 64.28%, a 177.0% increase from a year earlier, with the FY2025 full-year figure at 64.28%, up 244.0% from the prior year.
• Gross Margin for Q1 2026 stood at 63.47%, down from 64.14% in the prior quarter.
• Over the last five years, Gross Margin for NAGE reached as high as 65.0% in Q2 2025 and fell as low as 57.23% in Q4 2022.
• Historically, Gross Margin has averaged 61.69% across 5 years, with a median of 61.04% in 2023.
• Across the five-year window, Gross Margin tumbled 397 bps in 2022 and soared 478 bps in 2025, its largest moves.
• Year by year, Gross Margin stood at 57.23% in 2022, then rose by 7 bps to 61.04% in 2023, then advanced by 2 bps to 62.48% in 2024, then climbed by 3 bps to 64.14% in 2025, then decreased by 1 bps to 63.47% in 2026.
• Per Business Quant data, the three most recent Gross Margin figures were 63.47% in Q1 2026, 64.14% in Q4 2025, and 64.52% in Q3 2025.